Optimum Perspectives Optimum Strategic Communications

For this week’s podcast, our in-house IR expert, and ex-Fund Manager Eva Haas interviewed Dan Mahony, Chairman of the BioIndustry Association (BIA), following his appointment as UK Life Sciences Investment Envoy to hear his plans for championing the UK’s Life Sciences industry. Read the insight piece here: A profile of Dan Mahony, the UK Government’s Life Sciences Investment Envoy.
optimumcomms.com/
Follow us and subscribe for new episodes highlighting the latest innovation and developments in life sciences, with industry leaders of the healthcare sector.
Available on all major platforms: Apple, Spotify, Google, Amazon Music, Tune In, Castbox, Deezer and more! Follow and Subscribe today.
#optimumperspectivespodcast #podcast #lifesciences #investment #stockmarkets

Hosted on Acast. See acast.com/privacy for more information.

Stress urinary incontinence (SUI) is a common and debilitating problem for many women, particularly after childbirth or in later years. 
Yet, despite this, treatment options are limited, held back by a lack of research into medical products focused on women’s health. 
Versameb, hopes to change this with a novel mRNA therapy that rebuilds the urinary sphincter and is about to enter clinical trials. In this podcast, Richard Staines from Optimum Strategic Communications caught up with the Versameb team to find out more. Read the insight piece here: Versameb: Revolutionizing SUI therapy with mRNA technology – Optimum Strategic Communications (optimumcomms.com).
https://www.optimumcomms.com/ / https://versameb.com/
Follow us and subscribe for new episodes highlighting the latest innovation and developments in life sciences, with industry leaders of the healthcare sector.
Available on all major platforms: Apple, Spotify, Google, Amazon Music, Tune In, Castbox, Deezer and more! Follow and Subscribe today.
#optimumperspectivespodcast

Hosted on Acast. See acast.com/privacy for more information.

Our host Richard Staines, Account Director at Optimum, discusses the latest clinical findings from inobrodib, an oral cancer therapy developed by the UK biotech CellCentric.
In our first episode, we hear from Jan Ross, a patient who discusses the pressing need for new therapies for multiple myeloma with fewer side effects. We also talked to top cancer experts – Tim Somervaille of the Christie Hospital in Manchester, Karen Knudsen, Chief Executive of the American Cancer Society, Dr Leif Bergsagel, consultant in the Division of Hematology and Medical Oncology, at the Mayo Clinic in Arizona, and Will West, CEO of CellCentric.
Despite recent medical advances, treating haematological cancer remains a considerable challenge. CAR-T cell therapies have shown incredible efficacy against some forms of blood cancer, but side-effects are fearsome, and they don’t always work. Conventional therapies may require injections and regular inconvenient visits to the hospital. And CAR-T cell therapies are hugely expensive for healthcare systems to buy and administer to patients because of the workload for staff monitoring side effects. A UK biotech, CellCentric has seen an opening for an oral therapy, based on a small molecule drug, that could treat multiple myeloma and could be taken by patients in their own home.
www.optimumcomms.com / www.cellcentric.com
Follow us and subscribe for new episodes highlighting the latest innovation and developments in life sciences, with industry leaders of the healthcare sector.
Available on all major platforms: Apple, Spotify, Google, Amazon Music, Tune In, Castbox, Deezer and more! Follow and Subscribe today.
#optimumperspectivespodcast

Hosted on Acast. See acast.com/privacy for more information.